Complement C1s 詳細
Molecule Name
Complement C1s
分子の別称
EDSPD2
Drug Development Progress
治験薬の数5
市販薬剤の数4
研究＆開発段階Approved
ターゲットの別称
EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
バックグランド
Complement C1s is a serine protease and a key component of the C1 complex in the classical complement pathway. One C1q molecule binds to a tetramer composed of two C1r and two C1s proteases to form the intact C1 complex. C1s circulates as a zymogen until activated by proteolytic cleavage from activated C1r. Its essential function is to cleave complement components C4 and C2, thereby initiating the formation of the C3 convertase (C4b2a). This step is critical for triggering downstream immune effector functions, including opsonization, inflammation, and membrane attack complex formation.
Complement C1s 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Complement-C1 inhibitor protein (Octapharma) | Phase 3 Clinical | Octapharma | Angioedemas, Hereditary | 詳細 | |
| Riliprubart | BIVV-020; SAR-445088; TNT-020 | Phase 3 Clinical | True North Therapeutics | Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic | 詳細 |
| C1 esterase inhibitor (Boya Bio-Pharmaceutical) | Phase 3 Clinical | Boya Bio-Pharmaceutical Group Co Ltd | Angioedemas, Hereditary | 詳細 | |
| Claseprubart | DNTH103; DNTH-103 | Phase 3 Clinical | Dianthus Therapeutics Inc | Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 詳細 |
| C1 esterase inhibitor (Chengdu Institute of Biological Products) | Phase 1 Clinical | Chengdu Institute Of Biological Products Co Ltd | Angioedemas, Hereditary | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Conestat alfa | rhC1-INH | Approved | Pharming Group Nv | Rhucin, Esterasine, Ruconest | EU | Angioedemas, Hereditary | Pharming Group Nv | 2010-10-28 | Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency | 詳細 |
| Sutimlimab | BIVV-009; TNT-009 | Approved | True North Therapeutics | ENJAYMO | United States | Anemia, Hemolytic, Autoimmune | Recordati Rare Diseases Inc | 2022-02-04 | Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic | 詳細 |
| Complement C1 inhibitor protein (Shire ViroPharma) | C1 INH-nf; C1-INH; SHP-616 | Approved | Sanquin Plasma Products Bv | Cinryze, Cetor | United States | Angioedemas, Hereditary | null | 2008-10-10 | Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation | 詳細 |
| C1 esterase inhibitor (Human, CSL Behring) | BI-3.012; CSL-830; CSL-842; CE-1145 | Approved | Csl Behring Llc | Berinert, Haegarda, Berinert 2000 | Japan | Angioedemas, Hereditary | Csl Behring Llc | 1990-06-29 | Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation | 詳細 |